Madrigal Pharmaceuticals is a biopharmaceutical company focused on innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH).
Key features:
FDA-approved treatment for MASHFocus on halting or reversing liver scarringLeading clinical development program in MASHResearch on additional populations with high unmet needInnovative therapeutic approach using THR-β agonism
Pfizer is a leading biopharmaceutical company dedicated to discovering and developing innovative medicines and vaccines.
Key features:
Innovative cancer treatmentsComprehensive vaccine developmentPatient assistance programsResearch and development in chronic diseasesGlobal health initiatives
Comanche Biopharma is dedicated to making pregnancies safer through innovative therapies.
Key features:
Development of investigational siRNA medicineFocus on preterm preeclampsiaCommitment to evidence-based therapiesAccessibility for all women and babiesSupport resources for patients and survivors
A clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders.
Key features:
Genetics-based therapeutic targetsPatient-guided development strategiesEfficient clinical development pathsTranslational tools for validationFocus on neuronal excitation-inhibition balance
A biopharmaceutical company focused on drug discovery and development for autoimmune and inflammatory diseases.
Key features:
Scalable drug discovery modelDiversified portfolio of programsFocus on patient outcomesCommitment to scientific excellenceStrong leadership team with industry experience
Aclaris Therapeutics is a biopharmaceutical company focused on innovative treatments for immuno-inflammatory conditions.
Key features:
Kinase inhibition for drug developmentNovel small and large molecule drugsMonoclonal and bispecific antibody developmentInnovative biologic therapiesFull-service drug discovery and early development
A clinical-stage biopharmaceutical company focused on precision small molecule medicines for CNS disorders.
Key features:
Precision targeting of neuronal receptor complexesMinimization of side effectsDevelopment of small molecule medicinesFocus on CNS disordersUtilization of RAP technology platform
Developing novel therapeutics for metabolic and endocrine disorders.
Key features:
Development of first-in-class therapiesClinical trials for multiple compoundsFocus on safety and tolerability in trialsInnovative therapeutics for metabolic disordersOral and subcutaneous formulations
A biopharmaceutical company focused on developing next-generation therapies for patients with limited treatment options.
Key features:
Development of next-generation therapiesFocus on oncology and complex health conditionsCommitment to ethical standardsPatient-first approachCollaboration and impact-driven culture
A biopharmaceutical company focused on cancer therapeutics.
Key features:
Acquisition of novel therapeuticsDevelopment of cancer treatmentsCommercialization of FDA approved therapiesConducting clinical trials
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases.
Key features:
Inhaled recombinant GM-CSFPhase 3 clinical developmentFocus on rare respiratory diseases
A biopharmaceutical company dedicated to transforming innovation into value through new classes of medicine.
Key features:
Enhanced on-target efficacyOral administration capabilitiesImproved tolerabilityStrong clinical trial successRegulatory approval support
A pioneering biopharmaceutical company focused on RNA interference therapeutics.
Key features:
RNAi-based gene silencingFocus on rare and prevalent diseasesPatient-centered innovationRobust pipeline of investigational therapeuticsCommitment to corporate responsibility
Advancing novel antibody-based therapies to transform the lives of cancer patients.
Key features:
Novel antibody-drug conjugates (ADCs)Targeting specific molecular signaturesGlobal clinical development experienceCompanion diagnostics for patient selectionMulti-asset pipeline
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing treatments for pulmonary hypertension.
Key features:
Development of investigational drugsFocus on pulmonary arterial hypertensionFocus on pulmonary hypertension associated with interstitial lung diseaseCommitment to enhancing patient livesStrengthening relationships with stakeholders